Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement
06/10/2026 12:56
BRIEF-Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement Oct 6 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
REGENERON PHARMACEUTICALS - SANOFI ENTER SIXTH AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT - SEC FILING
REGENERON PHARMACEUTICALS - IPR&D CHARGE EXPECTED TO REDUCE Q3 2026 GAAP AND NON-GAAP EPS BY $0.18 - SEC FILING
Source text: [ID:n0001104659-26-113895]
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement